Haemonetics Corporation (NYSE:HAE), a prominent player in the medical products industry, specializing in blood management solutions, received a maintained "Buy" rating from Needham on August 7, 2025, although the price target was lowered from $84 to $68. At that time, the stock was trading at $57.58, reflecting market reactions to recent financial disclosures.
In the quarter ending June 2025, Haemonetics reported revenue of $321 million, a 4.4% decline from the previous year. Despite this, the revenue exceeded the Zacks Consensus Estimate of $303 million by 5.97%, as highlighted by Zacks. This indicates that while the company faced challenges, it managed to outperform market expectations.
The company's earnings per share (EPS) for the quarter were $1.10, up from $1.02 in the same period last year. This surpassed the consensus EPS estimate of $1.01 by 8.91%. The positive earnings surprise suggests that Haemonetics is effectively managing its operations, even amid revenue declines.
Over the past four quarters, Haemonetics has exceeded consensus EPS estimates three times, demonstrating consistent performance. In the previous quarter, the company delivered an EPS of $1.24, surpassing expectations of $1.22, resulting in a +1.64% surprise. This track record may contribute to Needham's continued "Buy" rating.
Currently, HAE is priced at $56.12, experiencing a significant decrease of 25.93% from its previous levels. The stock has fluctuated between $56.02 and $72.08 during the day, with a market capitalization of approximately $2.7 billion. Despite recent challenges, Haemonetics remains a key player in the medical products industry.
